Cooperative Agreement 2422363
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$997K
Federal Agency
National Science Foundation
Awardee
Invvax, Inc. (XD11NMF7NB14)
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Cypress, CA 90630, USA
Similar Awards
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
This $2 million cooperative agreement from the National Science Foundation will support Protabit LLC in developing artificial intelligence-enabled antibody engineering approaches to generate neutralizing antibodies against SARS-CoV-2. Funded through Jul 2022 to Jun 2024 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the project aims to discover a large array of high-affinity neutralizing antibodies targeting multiple regions of the SARS-CoV-2 spike protein. This...
The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $13,946,446 Cooperative Agreement titled "PROVIDENT: PREPOSITIONING OPTIMIZED STRATEGIES FOR VACCINES AND IMMUNOTHERAPEUTICS AGAINST DIVERSE EMERGING INFECTIOUS THREATS" to the Albert Einstein College of Medicine. The overarching goal of this 5-year project is to deliver "plug-and-play" vaccine and therapeutic antibody...
This $1,000,000 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports research and development efforts by Akanocure Pharmaceuticals Inc. to optimize a novel, broad-spectrum antiviral and immunomodulatory agent for oral administration against coronaviruses. The project focuses on lead optimization, including the design, synthesis, and testing of analogs with improved drug-like properties for...
This Project Grant award of $1,000,000 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of Partillion Bioscience Corp's advanced antibody discovery workflows. The funding aims to enhance their specialized hydrogel microparticle technology called "nanovials" to enable ultra high-throughput screening and functional assessment of single B cells and antibody-secreting cells. This is expected...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Abwiz Bio Inc. a $561,538 Phase I Small Business Technology Transfer (STTR) grant under CFDA 93.855 - Allergy and Infectious Diseases Research. The grant will fund the development of neutralizing antibodies against Machupo virus, a New World arenavirus, using a stabilized-trimer immunogen. The goal is to identify and characterize antibodies that target multiple epitopes on the virus surface glycoprotein, which could lead...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $331,189 to develop a new, affordable technology for virus detection. The project integrates protein engineering and electrochemical biosensors to create a portable, room-temperature stable platform for virus testing in resource-limited environments. Key innovations include the use of stable enzymes that can be stored at ambient temperatures,...
The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...